ProCommunity: procalcitonin use in real-world US community hospital settings
| Autor: | Kathryn E. DeSear, Sue Ie, Trevor C. Van Schooneveld, Hoi Ching Cheung, Susan Ou, Noam Y. Kirson, Jacqueline J. Chritton, Philipp Schuetz, Philippe Thompson-Leduc |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Hospitals Community 030204 cardiovascular system & hematology Procalcitonin Sepsis 03 medical and health sciences 0302 clinical medicine parasitic diseases medicine Humans 030212 general & internal medicine Intensive care medicine Respiratory Tract Infections Aged Retrospective Studies Aged 80 and over business.industry General Medicine Length of Stay Middle Aged bacterial infections and mycoses medicine.disease Community hospital Anti-Bacterial Agents Clinical trial Biomarker (medicine) Female Stewardship business Biomarkers hormones hormone substitutes and hormone antagonists |
| Zdroj: | Current Medical Research and Opinion. 36:1529-1532 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1080/03007995.2020.1793748 |
| Popis: | Procalcitonin (PCT) is a biomarker that may help providers optimize antibiotic (AB) therapy. Numerous clinical trials have demonstrated the utility of PCT-guided decision algorithms in treating lower respiratory tract infections and sepsis, but evidence from real-world studies is limited. This study sought to evaluate the effects of PCT on select clinical outcomes in community hospitals.An observational, retrospective, case-control study was conducted. Hospitals from a large US hospital system were categorized into "treatment" and "control" hospitals. Treatment hospitals were those with in-house PCT testing, a pharmacy team tasked with PCT testing follow-up and results in the patient's electronic medical records alongside a recommendation on AB treatment. Control hospitals either did not have PCT testing available in house or sent out tests to a laboratory or neighboring facility. Patients from treatment hospitals were matched 1:1 to patients from control hospitals based on admission diagnosis code, sex, age and whether an intensive care unit admission was observed. Clinical outcomes included number of days of AB treatment, length of stay, 30 day readmissions, mortality and acute kidney injury. Comparisons were conducted using multivariable regressions accounting for clustering at the hospital level.Patients from treatment hospitals had significantly shorter hospital stays (-0.68 days, 95% CI: -1.26, -0.09;These findings suggest that PCT, along with specific treatment recommendations, may lead to shortened hospital stays with no adverse outcome on patient safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|